ClinicalTrials.gg
RecruitingNCT06222671Updated Mar 11, 2025

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

A Phase 2 interventional study of 608 and 608 in Axial Spondyloarthritis, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.

Primary conditionNon-Radiographic Axial SpondyloarthritisRegistry: Axial SpondyloarthritisReclassifiedWhy we changed it
Registry
Axial Spondyloarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Radiographic Axial Spondyloarthritis
Why
  1. The study's title name Non-Radiographic Axial Spondyloarthritis, a narrower term within Axial Spondyloarthritis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China — 6 open to participants now, 6 under way, 3 of them phase 3. Non-Radiographic Axial Spondyloarthritis · China.

Planned enrollment
6th of 10
180 · median 227
Started
2024
the only one that year
Phase 2
2 of 11
1 open now
Registered
6th of 11
by date
Lead sponsor
2 of 11
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Among the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 2, and was the 6th registered.

Non-Radiographic Axial Spondyloarthritis

33 studies on the registry are indexed under Non-Radiographic Axial Spondyloarthritis; 12 are open to participants now.

Browse Non-Radiographic Axial Spondyloarthritis studies →

Open to participants now

6 of the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Non-Radiographic Axial Spondyloarthritis studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the effect and safety of 608 in patients with nr-axSpA.

Read the detailed description

The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of 608 compared to placebo in patients with nr-axSpA.

03

Conditions studied

  • Axial Spondyloarthritis

Browse trials for

Keywords

  • non-radiographic axial spondyloarthritis
04

In context

Non-Radiographic Axial Spondyloarthritis Reclassified

33 studies on the registry are indexed under Non-Radiographic Axial Spondyloarthritis; 12 are open to participants now.

This study's planned enrollment of 180 is below the median of 225 across 20 interventional studies indexed under Non-Radiographic Axial Spondyloarthritis.

Browse Non-Radiographic Axial Spondyloarthritis studies →

Lead sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is the lead sponsor of 59 studies on the registry; 22 are open to participants now.

First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc..

Compared within Non-Radiographic Axial Spondyloarthritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Axial Spondyloarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female and male patients at least 18 years of age at the time of screening.
  2. Diagnosis of axial spondyloarthritis according to Ankylosing Spondylo Arthritis International Society (ASAS) axial spondyloarthritis criteria
  3. Objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)
  4. Total back pain as measured by NRS ≥ 4 at baseline

Exclusion criteria

Exclusion Criteria:

  1. Patients with other uncontrolled active inflammatory diseases.
  2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance
  3. Patients who have active , or infections as determined by positive results at Screening.
  4. History of cancer.
  5. Known or suspected history of .
  6. Known with allergic or intolerant to mometasone furoate spray or 608/placebo.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    608 Dose A

    608 Dose A subcutaneous (SC) injection.

    Drug: 608

  • Experimental
    608 Dose B

    608 Dose B subcutaneous (SC) injection.

    Drug: 608

  • Placebo comparator
    Placebo

    Placebo subcutaneous (SC) injection.

    Drug: Placebo

Interventions

  • Drug608

    608 subcutaneous (SC) injection.

  • Drug608

    608 subcutaneous (SC) injection.

  • DrugPlacebo

    Placebo subcutaneous (SC) injection.

07

What researchers measure

Primary outcomes

  1. The Percentage of Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response

    Assessment of Spondylo Arthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a NRS; 2. Patient's assessment of back pain, measured on a NRS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by NRS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by NRS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the NRS signifies higher severity.

    Time frame: From Baseline to Week 16

Secondary outcomes

  1. The Percentage of Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 20 Response

    Assessment of Spondylo Arthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a NRS; 2. Patient's assessment of back pain, measured on a NRS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by NRS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by NRS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the NRS signifies higher severity.

    Time frame: From Baseline to the Week 16

  2. 608 Concentration in Serum

    The concentration of 608 in Serum.

    Time frame: From Baseline to Week 24

08

Study locations

5 of 6 sites recruiting
  • Site 01
    Beijing, Beijing 100730, China
    Recruiting
  • Site 03
    Beijing, Beijing 100730, China
    Recruiting
    • Li Cui, MD · Contact13611271262@163.com · +86 13611271262
    • Li Cui, MD · Principal investigator
  • Site 05
    Chongqing, Chongqing 400010, China
    Recruiting
    • Ling Tang, MD · Contacthopetang@163.com · +86 13896018063
    • Ling Tang, MD · Principal investigator
  • Site 02
    Zhengzhou, Henan 450052, China
    Recruiting
    • Shenyun Liu, MD · Contactfccliusy2@zzu.edu.cn · +86 13837192659
    • Shenyun Liu, MD · Principal investigator
  • Site 04
    Nanjing, Jiangsu 210008, China
    Recruiting
    • Lingyun Sun, MD · Contactlingyunsun2012@163.com · +86 13705186409
    • Lingyun Sun, MD · Principal investigator
  • Site 06
    Shenzhen, Shenzhen 518020, China
    Not yet recruiting
    • Dongzhou Liu, MD · Contactliu_dz2001@sina.com · +86 13802257360
    • Dongzhou Liu, MD · Principal investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Sep 2025, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Jan 25, 2024
StartActual
Mar 22, 2024
Primary completionEst.
Sep 22, 2025
CompletionEst.
Nov 30, 2025
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06222671
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Mar 22, 2024
Primary completion
Sep 22, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Mar 11, 2025

Study contacts

Qinghong Zhou, BS
Contact
zhouqinghong@3sbio.com
18911301578
Qinghong Zhou, BS
study director · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Xiaofeng Zeng, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion